LabCorp Introduces HIV-1 Next Generation Sequencing Assay to Support Drug Regimen Changes in HIV Suppressed Patients

GenoSure Archive SM is the first genotypic drug resistance assay to interrogate HIV-1 DNA BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 20, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) and Monogram Biosciences, Inc. , part of the LabCorp Specialty Testing Group , today

LabCorp’s Acquisition of LipoScience Clears Antitrust Approval

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 15, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 1, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Announces Agreement to Acquire LipoScience

Acquisition Price of $5.25 Per Share in All Cash Transaction NMR LipoProfile test expands LabCorp’s offering of personalized diagnostic tests BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 25, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) and LipoScience, Inc.

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 12, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of September 12, 2014 to March 11, 2015 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp’s Enlighten Health Launches Innovative Genomics Initiative

Enlighten Health Genomics Aims to Make Genetic Profiles a Routine Part of Clinical Decisions BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 4, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ; NYSE: LH) announced today the launch of Enlighten Health Genomics, a new business that builds on

LabCorp Announces the Availability of InformaSeqSM Non-Invasive Prenatal Test

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 19, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of the informaSeq Prenatal Test. The informaSeq Prenatal Test is an advanced, non-invasive, next-generation prenatal screening assay that can

Laboratory Corporation of America® Holdings Announces 2014 Second Quarter Results and Increases 2014 EPS Guidance

Sales of $1.52 billion Diluted EPS of $1.64 ; Adjusted EPS of $1.84 Operating Cash Flow of $207 million ; Free Cash Flow of $159 million 2014 Adjusted EPS guidance raised to $6.50 - $6.75 BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 18, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® )

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 1, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Announces the Availability of Luminex xTAG® CYP2D6 Genotype Assay

BURLINGTON, N.C. --(BUSINESS WIRE)--May 19, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of the xTAG ® CYP2D6 Kit v3 from Luminex Corporation (NASDAQ: LMNX). The xTAG CYP2D6 Kit v3 is an FDA cleared qualitative genotyping assay that